Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Jan 4, 2026
Reporting period
Not applicable
Filed with the SEC
Jan 5, 2026
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0002036798-26-000002
Filed / recorded
Jan 5, 2026, 10:55 PM UTC
Added to OQRO
Oct 7, 2026, 5:52 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Ovid Therapeutics Inc.
Issuer CIK
1636651
Ticker
OVID
Reporting person
Margaret A. Alexander
Relationship
Director, Officer
Officer title
President and CEO
Security
Employee Stock Option (right to buy)
Table
Derivative (Table II)
Transaction date
Jan 4, 2026
Transaction code
A
Shares / units
890,000
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
890,000
Ownership form
Direct
Amendment
No
Footnotes from the filing
25% of the shares subject to the Stock Option will vest and become exercisable on January 1, 2027 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date.